The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2023

Filed:

Nov. 13, 2020
Applicant:

Liposcience, Inc., Morrisville, NC (US);

Inventors:

James D. Otvos, Apex, NC (US);

Irina Y. Shalaurova, Cary, NC (US);

Dennis W. Bennett, Shorewood, WI (US);

Justyna E. Wolak-Dinsmore, Durham, NC (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/49 (2006.01); A61B 5/055 (2006.01); G01N 24/08 (2006.01); G01R 33/46 (2006.01); G16H 50/30 (2018.01); G01R 33/465 (2006.01); A61B 5/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/49 (2013.01); A61B 5/0044 (2013.01); A61B 5/055 (2013.01); A61B 5/7275 (2013.01); G01N 24/08 (2013.01); G01R 33/465 (2013.01); G01R 33/4625 (2013.01); G16H 50/30 (2018.01); A61B 2576/023 (2013.01); G01N 2333/47 (2013.01); G01N 2333/4728 (2013.01); G01N 2800/324 (2013.01); G01N 2800/50 (2013.01);
Abstract

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of 'GlycA' in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.


Find Patent Forward Citations

Loading…